AstraZeneca is asking a court to immediately stop generic drugmakers from their plans to make and sell generic forms of ...

This would reverse progress toward curbing drug shortages. AstraZeneca scrapped plans to invest $558.3 million in its vaccine ...

AstraZeneca scrapped plans for a £450 million UK vaccine plant after rejecting a £78 million government offer, citing ...

AstraZeneca investors will look past another strong set of quarterly results on Thursday to focus on the main issue ...

A revival in AstraZeneca Plc shares faces a key test this week, with more likely to hinge on the drugmaker’s ability to ...

Astra is due to pay Daiichi US$175 million in milestones after the US approval, the companies said. Enhertu is cleared in the ...

CORE EARNINGS PER SHARE: Core earnings per share are expected to rise to $2.07 from $1.45 the year prior, according to the same consensus. AstraZeneca's stock is up 7.9% since the start of 2024.

AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company’s future looks bright.

Panjim: The Goa Health Department, alongside AstraZeneca and Qure.ai, is launching multiple initiatives to improve cancer ...

The green light from the European Medicines Agency is the first backing in the EU for the medicine, following its approval in ...

Trade Secretary Cristina Roque reported on Saturday that the British-Swedish pharmaceutical AstraZeneca expressed interest in ...